Drug Profile
Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University
Alternative Names: Antiviral therapeutics - Assembly Biosciences; Core Protein Allosteric Modulators; CpAMsLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Indiana University
- Developer Assembly Biosciences; Indiana University
- Class Antivirals; Small molecules
- Mechanism of Action Viral core protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 05 Oct 2020 Preclinical development in Hepatitis-B is underway in USA (PO) (9304627; Assembly Biosciences Pipeline)
- 20 Aug 2018 Preclinical development in Hepatitis-B is underway in USA (PO) (9247174; Assembly Biosciences Pipeline)